Amicus Therapeutics Inc (NASDAQ: FOLD) has reported E.P.S. of $-0.07 for its third fiscal quarter (ending September 30) versus $-0.12 for the same period a year ago. Relative to the consensus estimate of $-0.08, this was a premium of $0.01. For the latest four quarters through September 30, E.P.S. were $-0.59 compared to $-0.92 a year ago.
Recent Price Action
Amicus Therapeutics Inc (NASDAQ: FOLD) stock closed at $11.36 on 11/8/23 after a large decline of -3.0%. The stock has risen 3.6% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, FOLD is expected to be a major Value Builder.
Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Amicus Therapeutics has a very low Appreciation Score of 1 but a neutral Power Rating of 57, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment